Paper Details

  1. Home
  2. Paper Details

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.

Author: AbrahamIvo, AnwerFaiz, IftikharAhmad, KapoorVikas, LatifAzka, McBrideAli, MushtaqAdeela, RiazIrbaz Bin, ZahidUmar

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Standard treatment for newly diagnosed multiple myeloma often involves a combination of three drugs, including a proteasome inhibitor like bortezomib. While effective, bortezomib can cause nerve problems (peripheral neuropathy). Carfilzomib (CFZ), another proteasome inhibitor, is more selective and has fewer side effects, including a lower risk of nerve problems. Studies show that CFZ is as effective as bortezomib and has a better safety profile, suggesting that it could be used as a first-line treatment for all types of multiple myeloma. However, more research is needed to determine the best dose of CFZ.
Paper Details　
Original Abstract of the Article :
Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids. Despite its notable efficacy, bortezomib has side effects like peripheral neuropathy (PNP) with reported incidence of grade ≥3 PNP betw...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29650268

データ提供：米国国立医学図書館（NLM）

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Multiple Myeloma

This systematic review assesses the efficacy and toxicity profile of carfilzomib (CFZ)-based regimens in treating multiple myeloma, a type of blood cancer. CFZ, a proteasome inhibitor, is a promising alternative to bortezomib, another commonly used proteasome inhibitor, due to its high selectivity and lower rates of peripheral neuropathy (PNP), a common side effect of bortezomib.

Carfilzomib's Advantages

The review found that CFZ-based regimens demonstrated comparable or even superior efficacy to bortezomib-based regimens, with a significantly more favorable adverse event profile. In newly diagnosed multiple myeloma (NDMM), CFZ-based regimens were associated with deeper, more rapid, and sustainable responses, supporting their potential use as frontline therapy across different risk categories.

Considerations and Future Directions

Despite its advantages, CFZ-based regimens are associated with a high incidence of grade ≥3 hypertension (HTN). The review highlights the need for close monitoring of blood pressure in patients receiving CFZ. Further research is needed to optimize CFZ dosing and explore its use in combination with other therapies for both NDMM and relapsed and refractory multiple myeloma (RRMM).

Dr. Camel's Conclusion

This research provides valuable insights into the evolving landscape of multiple myeloma treatment. Just as a desert traveler must adapt to changing terrain, researchers are constantly seeking new and improved approaches to combat this challenging disease. This review highlights the potential benefits of CFZ-based regimens, offering hope for patients with multiple myeloma. However, it also underscores the importance of careful patient selection, dose optimization, and close monitoring to mitigate potential side effects and optimize outcomes. The future of multiple myeloma treatment holds promise, and researchers are diligently working to develop even more effective and personalized therapies.
Date :
  1. Date Completed 2018-05-24
  2. Date Revised 2023-11-05
Further Info :

Pubmed ID

29650268

DOI: Digital Object Identifier

NIHMS948694

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.